Korea Investment CORP Acquires 29,700 Shares of Alexion Pharmaceuticals, Inc. (ALXN)

Share on StockTwits

Korea Investment CORP lifted its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 25.0% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 148,274 shares of the biopharmaceutical company’s stock after purchasing an additional 29,700 shares during the period. Korea Investment CORP’s holdings in Alexion Pharmaceuticals were worth $18,408,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Edge Wealth Management LLC increased its stake in Alexion Pharmaceuticals by 20.6% in the second quarter. Edge Wealth Management LLC now owns 2,338 shares of the biopharmaceutical company’s stock valued at $290,000 after acquiring an additional 400 shares during the last quarter. Peregrine Capital Management LLC increased its stake in Alexion Pharmaceuticals by 0.3% in the second quarter. Peregrine Capital Management LLC now owns 149,608 shares of the biopharmaceutical company’s stock valued at $18,574,000 after acquiring an additional 457 shares during the last quarter. Investment Management of Virginia LLC increased its stake in Alexion Pharmaceuticals by 10.1% in the first quarter. Investment Management of Virginia LLC now owns 5,230 shares of the biopharmaceutical company’s stock valued at $583,000 after acquiring an additional 480 shares during the last quarter. World Asset Management Inc increased its stake in Alexion Pharmaceuticals by 3.4% in the second quarter. World Asset Management Inc now owns 14,735 shares of the biopharmaceutical company’s stock valued at $1,829,000 after acquiring an additional 487 shares during the last quarter. Finally, Atria Investments LLC increased its stake in Alexion Pharmaceuticals by 21.7% in the second quarter. Atria Investments LLC now owns 2,732 shares of the biopharmaceutical company’s stock valued at $339,000 after acquiring an additional 488 shares during the last quarter. 93.62% of the stock is currently owned by institutional investors.

A number of research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $152.00 price objective on the stock in a research note on Monday, July 16th. BidaskClub raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 10th. ValuEngine raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 12th. Jefferies Financial Group reissued a “hold” rating and issued a $123.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, July 27th. Finally, Stifel Nicolaus cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price objective for the company from $154.00 to $130.00 in a research note on Tuesday, August 7th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and seventeen have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $157.56.

In other Alexion Pharmaceuticals news, CFO Paul J. Clancy sold 5,241 shares of the business’s stock in a transaction on Tuesday, July 10th. The shares were sold at an average price of $131.11, for a total transaction of $687,147.51. Following the sale, the chief financial officer now owns 93,309 shares of the company’s stock, valued at $12,233,742.99. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.35% of the company’s stock.

NASDAQ ALXN opened at $117.27 on Friday. The firm has a market cap of $26.17 billion, a price-to-earnings ratio of 22.73, a P/E/G ratio of 1.13 and a beta of 0.84. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $102.10 and a fifty-two week high of $147.29. The company has a current ratio of 2.72, a quick ratio of 2.27 and a debt-to-equity ratio of 0.33.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.58. The firm had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $976.81 million. Alexion Pharmaceuticals had a negative net margin of 2.68% and a positive return on equity of 15.21%. The company’s revenue was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.56 earnings per share. sell-side analysts predict that Alexion Pharmaceuticals, Inc. will post 6.45 earnings per share for the current year.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Featured Story: Risk Tolerance

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply